Nektar says Phase 2b REZOLVE-AA trial posts new 6-month off-treatment rezpegaldesleukin data in severe alopecia areata

• Nektar flagged new Phase 2b rezpegaldesleukin data in alopecia areata for future presentation at EADV 2026 in Vienna.
• The update will cover off-treatment follow-up, focusing on whether hair regrowth benefits persist once dosing stops.
• Separate EADV oral sessions will present atopic dermatitis maintenance findings, highlighting sustained symptom improvement with less frequent dosing.
• A late-breaking atopic dermatitis biomarker readout will detail early molecular changes consistent with drug activity.
• Nektar scheduled an Oct. 1, 2026 investor webcast to discuss the off-treatment alopecia areata results.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nektar Therapeutics published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609280800PR_NEWS_USPR_____SF57582) on September 28, 2026, and is solely responsible for the information contained therein.